The first OV, a second-generation herpes simplex virus type 1 (HSV-1) armed with granulocyte macrophage-colony stimulating factor (GM-CSF), obtained US FDA and the European Medicine Agency approvals in 2015 for melanoma [15]. This evidence concerns the gene CSF2 and melanoma.